Application of Sugammadex in Thyroid Surgery: a Randomized Controlled Trial.

Application of Sugammadex in Thyroid Surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030083

Enrollment

Unknown

Registered

2020-02-22

Start date

2020-02-28

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid neoplasms

Interventions

experimental group:Intravenous injection of Sodium Sugense 2mg/kg

control group:Neostigmine 40 ug/kg was injected intravenously with atropine 20 ug/kg.

Eligibility

Sex/Gender

All

Age

18 Years to 62 Years

Inclusion criteria

Inclusion criteria: 1. The patients who are going to undergo thyroidectomy, such as total thyroidectomy, subtotal thyroidectomy, etc.; 2. Aged 18-75 years; 3. ASA 1-3 grade.

Exclusion criteria

Exclusion criteria: 1. patients with serious cardiopulmonary disease; 2. patients with liver and kidney failure; 3. patients with cerebrovascular diseases; 4. allergic to Sugammadex, Rocur-Ononium, or Neostigmine; 5. predicting difficult airway patients; 6. failure to cooperate with TOF; 7. patients with speech disorders.

Design outcomes

Primary

Measure	Time frame
Ktime;Rtime;a Angel;ma;Four items of blood coagulation;	—

Countries

China

Contacts

Public ContactKathy Fang

The First Affiliated Hospital of SYSU

fang_jieyu@163.com+86 13660121136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026